State of the art in platelet transfusion therapy

Transfusion Science

Volumn 17, Issue 4, 1996, Pages 575-584

  Murphy, M F ^a,b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE CONCENTRATE;

BLOOD TRANSFUSION REACTION; CONFERENCE PAPER; INFECTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0346614613     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(96)90093-4     Document Type: Conference Paper

References (41)

1. Hersh EM, Bodey GP, Boyd AN, Freireich EJ: Causes of death in acute leukaemia: A ten year study of 414 patients from 1954-1963. JAMA 1965; 193:99-103.
2. Han T, Stutzman L, Cohen E, Kim U: Effect of platelet transfusion on haemorrhage in patients with acute leukaemia. Cancer 1966; 19:1937-1942.
3. Slichter S: Controversies in platelet transfusion therapy. Annu Rev Med 1980; 31:509-540.
4. National Institutes of Health Consensus Conference: Platelet transfusion therapy. JAMA 1987; 257:1777-1780.
5. British Committee for Standards in Haematology: Guidelines for platelet transfusions. Transfus Med 1992; 2:311-318.
6. Kirkley SA, Blumberg N: Use of single donor platelets. Blood Reviews 1994; 8:142-147.
7. Bertolini F, Rebulla P, Porretti L, Murphy S: Platelet quality after 15-day storage of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium. Transfusion 1992; 32:9-16.
8. Bertoloni F, Rebulla P, Riccardi D, Cortellaro M, Ranzi ML, Sirchia G: Evaluation of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium. Transfusion 1989; 29:605-609.
9. Hogman CF: New trends in the preparation and storage of platelets. Transfusion 1992; 32:3-6.
10. Klein HG: Wolf in wolf's clothing: Is it time to raise the bounty on the passenger leukocyte? Blood 1992; 80:1865-1868.
11. Bordin JO, Heddle NM, Blajchman MA: Biologic effects of leukocytes present in transfused cellular blood products. Blood 1994; 84:1703-1721.
12. Perkins HA, Payne R, Ferguson J, Wood M: Nonhemolytic transfusion reactions. Vox Sang 1966; 11:578-600.
13. Dzik WH: Leukoreduced blood components: 'You can filter now or you can filter later'. Transfus Sci 1992; 13:207-210.
14. Brand A: Passenger leukocytes, cytokines, and transfusion reactions. N Engl J Med 1994; 331:670-671.
15. Muylle L, Joos M, Wouters E, De Bock R, Peetermans ME: Increased tumor necrosis factor (TNF), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: Relationship between TNF and IL-6 levels and febrile transfusion reactions. Transfusion 1993; 33:195-199.
16. Williamson LM, Wimperis JZ, Williamson et al: Bedside filtration of blood products in the prevention of HLA alloimmunization - A prospective randomized study. Blood 1994; 83:3028-3035.
17. Blajchman MA, Bardossy L, Carmen RA, Goldman M, Heddle NM, Singal DP: An animal model of allogeneic donor platelet refractoriness: The effect of time on leukocyte depletion. Blood 1992; 79:1371-1375.
18. Novotny VMJ, van Doom R, Witvliet MD, Claas FHJ, Brand A: Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: A prospective study. Blood 1995; 85:1736-1741.
19. Rawal B, Benedict Yen TS, Vyas GN, Busch M: Leukocyte filtration removes infectious particulate debris but not free virus derived from experimentally lysed HIV-infected cells. Vox Sang 1991; 60:214-218.
20. Heddle NM, Blajchman MA: The leukodepletion of cellular blood products in the prevention of HLA alloimmunization and refractoriness to allogeneic platelet transfusions. Blood 1995; 85:603-606.
21. Perkins HA: Is white cell reduction cost-effective? Transfusion 1993; 33:626-628.
22. Consensus Conference: Leucocyte depletion of blood and blood components. Royal College of Physicians, Edinburgh, 1993.
23. Slichter SJ: Mechanisms and management of platelet refractoriness, in Nance SJ, (ed.): Tranfusion Medicine in the 1990s. Arlington VA, American Association of Blood Banks, 1990, 95-179.
24. Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZS, Lister Ta, Waters AH: Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994; 66:200-205.
25. Schiffer CA: Prevention of alloimmunization against platelets. Blood 1991; 77:1-4.
26. Murphy WG, Palmer JP, Green RHA: The management of haemorrhage in the refractory non-alloimmunized thrombo-cytopenic patient. Vox Sang 1994; 67 (suppl.3):99-103.
27. Murphy MF: Transfusion management of patients alloimmunized to platelet and leukocyte antigens, in Pamphilon D, (ed.): Modern Transfusion Medicine. Boca Raton, FL, CRC Press, 1994, 125-138.
28. Von dem Borne AEGKr., Ouwehand WH, Kuijpers RWAM: Theoretic and practical aspects of platelet crossmatching. Transfusion Med Fev 1990; 4:265-278.
29. Phekoo KJ, Hambley H, Win N, Murphy MF, Carr R, Schey S: Audit of practice in platelet refractoriness. Vox Sang (in press).
30. Schiffer CA: Prophylactic platelet transfusion. Transfusion 1992; 32:295-298.
31. Beutler E: Platelet transfusions: The 20,000 μL trigger. Blood 1993; 81:1411-1413.
32. Slichter SJ, Harker LA: Thrombocytopenia: Mechanisms and management of defects in platelet production. Clin Haematol 1978; 7:523-539.
33. Gmur J, Burger J, Schanz U, Fehr J, Schaffner A: Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 1991; 338:1223-1226.
34. Surgenor DM, Wallace EL, Hao SH, Chapman RH: Collection and transfusion of blood in the United States, 1982-1988. N Engl J Med 1989; 322:1646-1651.
35. Wallace EL, Surgenor DM, Hao HS, An J, Chapman RH, Churchill WH: Collection and transfusion of blood and blood components in the United States, 1989. Transfusion 1993; 33:139-144.
36. Wallace EL, Churchill WH, Surgenor DM, et al.: Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 1995; 35:802-812.
37. Pisciotto PT, Benson K, Hume H, et al: Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 1995; 35:498-502.
38. Kretschmer V: Platelet transfusions in Europe - analysis of the ESFH questionnaire. Infusiontherapie und Transfusionsmedizin 1995; 22 (suppl.2):55.
39. Kretschmer V, Huss B, Weber S, et al.: A contribution to indication and determination of therapeutical efficiency of platelet transfusion. Transfus Med 1993; 3 (suppl. 1):14.
40. Sheridan WP, Begley CG, Juttner CA, et al.: Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery afer high-dose chemotherapy. Lancet 1992; 339:640-644.
41. Kaushansky K: Thrombopoietin: The primary regulator of platelet production. Blood 1995; 86:419-431.